IBTA e-News October 2017 released

By 30th November 2017 January 5th, 2018 News archive
[30 October 2017] The IBTA's monthly e-News has now been released and has been emailed to all subscribers. To sign up to receive your copy, click here.

You can read the IBTA e-News October 2017 edition in full online here.

Some of the highlights from this month's include:

  • The Australian government has announced the launch of the Australian Brain Cancer Mission, which will receive receive AUD $50 million over the next 10 years under the Medical Research Future Fund alongside AUD $50 million contributions from charities and philanthropic partners.
  • The European Commission's Horizon 2020 Research and Innovation Framework Programme has awarded funding of almost €3.9 million to the GLIOTRAIN project, an initiative that will develop a European biomedical research training programme to investigate glioblastoma, training 15 ‘innovative, creative and entrepreneurial’ PhD students.
  • A study in Nature Medicine, has found that the approved chemotherapy agent erlotinib (used in the treatment of pancreatic cancer and non-small cell lung cancer) inhibits glucose processing in glioblastoma cells, making them more vulnerable to other treatments.
  • An international team of researchers has analysed the genetic profiles of over 1,000 paediatric and young adult high-grade gliomas or diffuse intrinsic pontine gliomas (DIPG) and found that these tumours had wide variability in the number of genetic abnormalities, ranging from a single genetic error to tens of thousands – among the highest number of mutations in any human cancer.
  • According to a report published in FESB Journal, researchers have developed a three-dimensional model of the human blood-brain-barrier, which could help in the development and testing of future brain tumour therapies.
  • Researchers from South Africa and the United States have found an association between HIV infection and high grade meningioma (WHO grade II/III) in young adults (under 35 years of age), compared to the general population.
  • Donations to a brain tumour research fund increased from $100,000 to $1.8 million on the day following the death of Gord Downie, the frontman for Canadian rock band Tragically Hip, according to news reports. Gord Downie died from a glioblastoma on October 17, 2017, aged 53.

Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 7,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.

To see an archive of existing e-News issues, click here.